Author

Drew E. Lewis

Observed names: D. Lewis, D.E. Lewis, Drew Lewis

Observed institutions: Pfizer (United States), Pharmerit (United States), Entasis Therapeutics (United States)

OpenAlex ID: A5034660908

Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)

2023 · Keith S Kaye, Andrew F Shorr, et al. · The Lancet Infectious Diseases · 350

Single-Dose Azithromycin Microspheres vs Clarithromycin Extended Release for the Treatment of Mild-to-Moderate Community-Acquired Pneumonia in Adults

2005 · Margaret A. Drehobl, Maria C. De Salvo, et al. · CHEST Journal · 71

Novel, Single-Dose Microsphere Formulation of Azithromycin versus 7-Day Levofloxacin Therapy for Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults

2005 · Joseph D'Ignazio, Marco A. Camere, et al. · Antimicrobial Agents and Chemotherapy · 69

Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

2025 · Alison Luckey, Manica Balasegaram, et al. · The Lancet · 58

Cost impact of hydroxocobalamin in the treatment of patients with known or suspected cyanide poisoning due to smoke inhalation from closed-space fires

2021 · Kafi N. Sanders, Jyoti Aggarwal, et al. · Burns · 14

Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers

2010 · John Davis, Frances Hackman, et al. · Clinical Therapeutics · 7

732. Microbiologic and clinical outcome concordance in the global phase 3 ATTACK trial: Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections

2022 · David Altarac, Alita Miller, et al. · Open Forum Infectious Diseases · 3

646. Subgroup Analyses of Microbiological Cure Rates by Baseline Zoliflodacin MIC and Susceptibility to Ciprofloxacin in Participants from the Global Zoliflodacin Phase 3 Randomized Controlled Trial

2026 · Sarah McLeod, Esther Bettiol, et al. · Open Forum Infectious Diseases · 1

675. Sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: A detailed safety review from the pivotal phase 3, global, randomized, active-controlled trial (ATTACK)

2022 · Drew Lewis, Khurram Rana, et al. · Open Forum Infectious Diseases · 1

225. Efficacy and safety of sulbactam-durlobactam are consistent across regions in the global ATTACK phase 3 trial in the treatment of carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections

2022 · Alita Miller, Adam B Shapiro, et al. · Open Forum Infectious Diseases · 1

734. Efficacy of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with extensively drug-resistant (XDR) and pan-drug resistant (PDR) Acinetobacter baumannii-calcoaceticus complex (ABC) infections

2022 · Alita Miller, Sarah McLeod, et al. · Open Forum Infectious Diseases · 1

Sulbactam-Durlobactam Treatment Is Associated with Lower Mortality from Index Acinetobacter Infections in the Attack Phase 3 Registrational Trial

2022 · D. Altarac, A.B. Shapiro, et al. · American Journal of Respiratory and Critical Care Medicine · 1

Comparison of taliglucerase alfa 30U/kg and 60U/kg in treatment-naïve pediatric patients with Gaucher disease

2015 · Ari Zimran, Derlis Emilio Gonzalez-Rodriguez, et al. · Molecular Genetics and Metabolism · 1

Zoliflodacin: non-inferior, but not equivalent? – Authors’ reply

2026 · Alison Luckey, Manica Balasegaram, et al. · The Lancet

P-443. Population Pharmacokinetics (PPK) Analysis of Eravacycline (ERV) to Support Dose Selection for a Trial in Pediatric Patients Aged 8 to Less Than 18 Years with Complicated Intra-Abdominal Infection (cIAI)

2026 · Claudia Jomphe, Nathalie H Gosselin, et al. · Open Forum Infectious Diseases

P-1206. Association of Sex Assigned at Birth and Sexual Orientation with Antimicrobial Susceptibility of Baseline Neisseria gonorrhoeae Isolates from Participants Recruited in the Global Zoliflodacin Phase 3 Randomized Controlled Trial

2026 · Sarah McLeod, Esther Bettiol, et al. · Open Forum Infectious Diseases

94 Cost Impact of Hydroxocobalamin as Treatment for Patients With Known or Suspected Cyanide Toxicity Due to Smoke Inhalation Injury

2017 · K.N. Sanders, J. Aggarwal, et al. · Annals of Emergency Medicine

Works count: 17

Citation count: 578

H-index: 6

I10-index: 5